Neoton Phlebo (Phosphocreatine Sodium)

Neoton Phlebo acts on myocardial energy metabolism and is used in several cardiovascular conditions.

• Ischemic heart disease: improves myocardial energy supply and supports contractile function.
• Myocardial infarction: helps restore ATP levels during acute ischemic injury.
• Cardiac surgery: provides metabolic support to the heart during operative stress.
• Peripheral vascular disease: enhances tissue perfusion by supporting cellular energetics.

• Phosphocreatine sodium delivers exogenous phosphocreatine that is rapidly phosphorylated to ATP by creatine kinase within myocardial cells. The increased intracellular ATP replenishes energy stores depleted during ischemia, stabilizing cellular membranes and enhancing contractile performance. By supporting the phosphocreatine‑ATP shuttle, the drug aids in maintaining myocardial function under reduced oxygen supply. This metabolic boost can improve hemodynamic parameters and reduce the extent of ischemic injury during acute events.

Adverse reactions to Neoton Phlebo are reported primarily in the context of intravenous administration.

Common Side Effects

• Injection site pain: mild discomfort at the infusion site.
• Hypotension: transient drop in blood pressure during administration.
• Nausea: occasional feeling of nausea.
• Headache: mild to moderate headache.

Serious or Rare Side Effects

• Arrhythmias: potentially life‑threatening cardiac rhythm disturbances.
• Anaphylactic reaction: severe allergic response requiring immediate treatment.
• Hyperkalemia: elevated serum potassium levels.
• Metabolic acidosis: significant acid‑base imbalance.

When using Neoton Phlebo, clinicians should observe several safety considerations.

• Cardiac monitoring: continuous ECG and blood pressure monitoring during infusion.
• Renal function: assess kidney function before and during therapy.
• Electrolyte balance: monitor serum potassium and calcium levels.
• Contraindications: avoid in patients with known hypersensitivity to phosphocreatine or related compounds.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neoton Phlebo may interact with other agents that affect cardiac energetics or electrolyte status.

Major Interactions (Avoid)

• Concurrent use with high‑dose catecholamines: may exacerbate myocardial oxygen demand.
• Combination with other ATP‑donor drugs (e.g., adenosine): risk of additive cardiac effects.

Moderate Interactions (Monitor Closely)

• Diuretics that alter potassium: monitor electrolytes closely.
• Anticoagulants: increased bleeding risk if hypotension occurs.
• Beta‑blockers: may modify hemodynamic response, requiring dose adjustment.